U.S. authorities opened a formal review into Chinese state support and pricing practices in the biotech sector, with the International Trade Commission and related agencies scrutinizing whether government subsidies and pricing distortions disadvantaged American firms. Biocentury reported the investigation could lay groundwork for tariffs or other trade remedies and named AMED and several Western VCs tapping Japan incentives in context of cross‑border investment shifts. The trade review raises geopolitical and commercial risks for global biopharma supply chains and dealmaking. Companies with China exposure may face increased disclosure and potential policy actions; reporting sources include BioCentury and U.S. trade filings.